Overview: Chikungunya IgM TestIntroduction: The Chikungunya IgM Test detects IgM antibodies to Chikungunya virus, indicating recent infection causing fever or joint pain. Following 2023 IDSA guidelines, it uses an immunoassay for high sensitivity, aiding in infectious disease screening. This test is critical for guiding diagnosis, treatment, and improving outcomes in immunology for patients with suspected Chikungunya infection.
Other Names: Chikungunya IgM Assay, Viral Arthritis Test.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic accuracy.
Historical Milestone: Chikungunya antibody testing began in the 2000s with viral outbreak research. IgM-specific assays emerged in the 2010s, improving diagnostic accuracy.
Purpose: Diagnoses recent Chikungunya infection, guides treatment, and monitors antibody levels in patients with fever or joint pain.
Test Parameters: 1. Chikungunya IgM
Pretest Condition: No fasting required. Collect serum or saliva at any time. Report symptoms like fever or joint pain, and list recent travel or medications.
Specimen: 2-5 mL serum (SST) or 1-2 mL saliva (sterile container). Centrifuge serum within 1 hour. Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document fever, joint pain, or recent travel to endemic areas. Include current medications, especially antipyretics or analgesics.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for supportive therapy.
Procedural Considerations: Uses an immunoassay to measure Chikungunya IgM antibodies. Results are available in 1-2 days, enabling rapid clinical decisions.
Factors Affecting Result Accuracy: Cross-reactivity with other viral infections may cause false positives. Hemolysis or improper storage can degrade samples.
Clinical Significance: Positive results confirm recent Chikungunya infection, prompting supportive therapy. Negative results may require PCR testing.
Specialist Consultation: Consult an infectious disease specialist for result interpretation. A rheumatologist referral is advised for persistent joint pain.
Additional Supporting Tests: Chikungunya PCR, IgG test, or dengue serology to confirm infection or rule out similar viruses.
Test Limitations: False positives may occur with related viruses. Results require clinical correlation with travel history.
References: IDSA Chikungunya Guidelines, 2023; Clinical Infectious Diseases, Weaver SC, 2022.
